7176-39-8

Basic information

• Product Name: 1-[4-(benzyloxy)phenyl]propan-2-amine
• Synonyms: 1-[4-(Benzyloxy)phenyl]-2-propanamine; 4-Benzyloxyamphetamine; alpha-Methyl-4-(phenylmethoxy)benzeneethanamine; Benzeneethanamine, alpha-methyl-4-(phenylmethoxy)-; Phenethylamine, p-(benzyloxy)-alpha-methyl-
• CAS NO: 7176-39-8
• Molecular Formula: C₁₆H₁₉NO
• Molecular Weight: 241.3282
• Mol File: 7176-39-8.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 378°C at 760 mmHg
• Flash Point: 180.3°C
• Density: 1.06g/cm³
• Vapor Pressure: 6.49E-06mmHg at 25°C
• Refractive Index: 1.574
• CAS DataBase Reference: 1-[4-(benzyloxy)phenyl]propan-2-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[4-(benzyloxy)phenyl]propan-2-amine(7176-39-8)
• EPA Substance Registry System: 1-[4-(benzyloxy)phenyl]propan-2-amine(7176-39-8)

Safety Data

• Hazardous Substances Data: 7176-39-8(Hazardous Substances Data)

Usage

Chemical class

Phenylpropanes A class of organic compounds that consist of a propane chain with a phenyl ring attached.

Derivative

Amphetamine It is a derivative of the stimulant drug amphetamine, sharing a similar structure.

Structure

Propan-2-amine backbone with a phenyl ring substituted with a benzyloxy group at the 4-position The compound's molecular structure features a propan-2-amine chain and a phenyl ring with a benzyloxy substitution.

Application

Medicinal chemistry It is commonly used as a precursor in the synthesis of various psychoactive substances and designer drugs.

Effects

Stimulant and psychoactive The compound has been reported to have stimulant and psychoactive effects, similar to other drugs in its class.

Legal status

Controlled substance Due to its potential for abuse and dependence, it is considered a controlled substance in many countries.

Usage

Research and development It is primarily used in the field of medicinal chemistry for research and development purposes, particularly in the synthesis of new psychoactive compounds.

Safety concerns

Potential for abuse and dependence The compound's stimulant and psychoactive properties raise concerns about its potential for abuse and dependence, leading to its classification as a controlled substance in many jurisdictions.

Upstream product

• 103-86-6 p-hydroxyamphetamine 
• 100-44-7 benzyl chloride 
• 7176-38-7 1-(4-Benzyloxyphenyl)-2-nitro-1-propen 
• 4397-53-9 p-benzyloxybenzaldehyde 
• 100780-36-7 (E)-1-(benzyloxy)-4-(2-nitroprop-1-enyl)benzene 
• 27566-05-8 4-(2-(benzylamino)propyl)phenol 
• 770-39-8 4-methoxyphenylacetone 

Downstream Products

• 103-86-6 p-hydroxyamphetamine 
• 136534-74-2 [2-(4-Benzyloxy-phenyl)-1-methyl-ethyl]-(3-phenyl-propyl)-amine 
• 608137-92-4 [2-(4-benzyloxy-phenyl)-1-methyl-ethyl]-(2-fluoro-ethyl)-amine 

Relevant articles and documents

A Bioinspired Synthesis of Polyfunctional Indoles

Polyfunctional indoles bearing substituents at C5 and C6 are prevalent in natural products, pharmaceuticals, agrochemicals, and materials. Owing to the remoteness of the C5 and C6 positions, indoles of this family can be difficult to prepare, and often require multistep syntheses. Herein, we describe a concise process that converts simple derivatives of tyrosine into 5,6-difunctionalized indoles by direct oxidation of C?H, N?H, and O?H bonds. Our work draws inspiration from the biosynthetic polymerization of tyrosine to make melanin pigments, but makes an important departure to provide well-defined indole heterocycles.

DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR

The present invention provides a compound of formula (I): wherein: ? R1 is a group selected from -CH2OH,-NH(CO)H and ? R2 is a hydrogen atom; or ? R1together with R2 form the group -NH-C(O)-CH=CH-, wherein the nitrogen atom is bound to the carbon atom in the phenyl ring holding R1and the carbon atom is bound to the carbon atom in the phenyl ring holding R2 ? R3a and R3bare independently selected from the group consisting of hydrogen atoms and C1-4alkyl groups, ? n represents an integer from 1 to 3; ? Ad represents 1-adamantyl or 2-adamantyl group, or a pharmaceutically-acceptable salt or solvate or stereoisomer thereof.

New amphetamine derivatives, antibodies against them and pharmaceutical compositions containing them

Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo to amphetamines are disclosed. Methods of preparing the hapten-carrier conjugates and therapeutic compositions are also disclosed. A therapeutic composition containing the hapte